fluoxetine has been researched along with Spinal Cord Injuries in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "Co-treatment with fluoxetine and vitamin C significantly attenuated BSCB permeability at 1 d after SCI." | 1.43 | Fluoxetine and vitamin C synergistically inhibits blood-spinal cord barrier disruption and improves functional recovery after spinal cord injury. ( Choi, HY; Lee, JY; Yune, TY, 2016) |
| "Fluoxetine treatment significantly inhibited messenger RNA expression of matrix metalloprotease 2, 9 and 12 after spinal cord injury." | 1.38 | Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury. ( Choi, HY; Kim, HS; Lee, JY; Oh, TH; Yune, TY, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, B | 1 |
| Alam, M | 1 |
| Tierno, A | 1 |
| Zhong, H | 1 |
| Roy, RR | 1 |
| Gerasimenko, Y | 1 |
| Lu, DC | 1 |
| Edgerton, VR | 1 |
| Borbély, Z | 1 |
| Csomó, BK | 1 |
| Kittel, Á | 1 |
| Gerber, G | 1 |
| Varga, G | 1 |
| Vizi, ES | 1 |
| Tysseling, VM | 1 |
| Klein, DA | 1 |
| Imhoff-Manuel, R | 1 |
| Manuel, M | 1 |
| Heckman, CJ | 1 |
| Tresch, MC | 1 |
| Ryu, Y | 1 |
| Ogata, T | 1 |
| Nagao, M | 1 |
| Sawada, Y | 1 |
| Nishimura, R | 1 |
| Fujita, N | 1 |
| Cristante, AF | 1 |
| Filho, TE | 1 |
| Oliveira, RP | 1 |
| Marcon, RM | 1 |
| Ferreira, R | 1 |
| Santos, GB | 1 |
| Scali, M | 1 |
| Begenisic, T | 1 |
| Mainardi, M | 1 |
| Milanese, M | 1 |
| Bonifacino, T | 1 |
| Bonanno, G | 1 |
| Sale, A | 1 |
| Maffei, L | 1 |
| Luedtke, K | 1 |
| Bouchard, SM | 1 |
| Woller, SA | 1 |
| Funk, MK | 1 |
| Aceves, M | 1 |
| Hook, MA | 1 |
| Lee, JY | 3 |
| Kang, SR | 1 |
| Yune, TY | 3 |
| Welling, LC | 1 |
| Welling, MS | 1 |
| Teixeira, MJ | 1 |
| Figueiredo, EG | 1 |
| Choi, HY | 2 |
| Kim, HS | 1 |
| Oh, TH | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 1 |
| Stolp-Smith, KA | 1 |
| Wainberg, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for fluoxetine and Spinal Cord Injuries
| Article | Year |
|---|---|
Serotonergic Facilitation of Forelimb Functional Recovery in Rats with Cervical Spinal Cord Injury.
Topics: Animals; Buspirone; Cervical Cord; Electromyography; Evoked Potentials, Motor; Female; Fluoxetine; F | 2021 |
Effect of rat spinal cord injury (hemisection) on the ex vivo uptake and release of [
Topics: Adrenergic Uptake Inhibitors; Animals; Female; Fluoxetine; Neurons; Norepinephrine; Rats; Rats, Wist | 2017 |
Constitutive activity of 5-HT
Topics: Animals; Baclofen; Female; Fluoxetine; Mice; Motor Neurons; Muscle Relaxants, Central; Receptor, Ser | 2017 |
Effects of Treadmill Training Combined with Serotonergic Interventions on Spasticity after Contusive Spinal Cord Injury.
Topics: Animals; Cyproheptadine; Female; Fluoxetine; Muscle Spasticity; Physical Conditioning, Animal; Rats; | 2018 |
Effects of antidepressant and treadmill gait training on recovery from spinal cord injury in rats.
Topics: Animals; Antidepressive Agents; Combined Modality Therapy; Disease Models, Animal; Evoked Potentials | 2013 |
Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury.
Topics: Animals; Disease Models, Animal; Fluoxetine; Gait; Male; Motor Activity; Motor Cortex; Neuronal Plas | 2013 |
Assessment of depression in a rodent model of spinal cord injury.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Disease Models, Ani | 2014 |
Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Drug Administration Schedule; Fluoxetine; Injections, In | 2015 |
Fluoxetine and Spinal Cord Injury: More Pleiotropic Effects?
Topics: Animals; Fluoxetine; Male; Microglia; Oligodendroglia; Selective Serotonin Reuptake Inhibitors; Spin | 2016 |
Fluoxetine and vitamin C synergistically inhibits blood-spinal cord barrier disruption and improves functional recovery after spinal cord injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Sy | 2016 |
Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury.
Topics: Animals; Blood-Brain Barrier; Cell Line; Enzyme Activation; Fluoxetine; Male; Matrix Metalloproteina | 2012 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
Antidepressant exacerbation of spasticity.
Topics: Adjustment Disorders; Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, D | 1999 |